-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Of the 18,000 large b-cell lymphoma patients diagnosed each year, only half can be successfully treated with chemotherapy
Manali Kamdar, MD, associate professor of the Department of Hematology at the University of Colorado School of Medicine and a member of the Columbia University Cancer Center, said: "About three-quarters of patients do not respond to initial therapy, and their survival time is only a few months
Improve treatment with new drugs
For the past four years, Kamdar has been the lead investigator of a global, multi-center, phase III clinical study, which aims to find out that Breyanzi (lisocabtagene maraleucel; Liso-cel) can improve the performance of these patients.
Kamdar said: "I am happy to represent all co-authors and say that this is a positive trial because it meets the primary endpoint of event-free survival
Kamdar said that it is also important that this drug is safer for patients than other CAR-T drugs, most of which are low-level side effects, such as cytokine release syndrome and nervous system side effects
Kamdal said: "We want to make sure that these things are effective, but if it is at the cost of higher toxicity, then you lose all meaning
Clinical trials benefit patients in CU cancer center
The phase III trial enrolled 184 patients from 47 locations around the world, most of which were at the University of Colorado Cancer Center and Uuchalth University Hospital
Camdal said: "We are the leader to ensure that our patients, not only from Colorado, but also from neighboring states such as Wyoming, New Mexico, and Kansas, will ultimately benefit from this product more quickly
Regulatory review
In the next two years, researchers will continue to follow patients in phase III clinical trials to track relapse rates and overall survival rates, but based on this study led by Kamdar, the drug's manufacturer Bristol Myers Squibb is eager for health / Regulatory authorities discuss the results
Kamdal said: "If we follow this study for a longer period of time, we actually end up extending the life of the patient, I wouldn't be surprised
###
